WithdrawnPhase 2NCT01203618
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Studying Functioning pituitary adenoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Morphotek
- Principal Investigator
- Bruce Wallin, MDMorphotek
- Intervention
- Farletuzumab(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2013
Study locations (1)
- Emory University, Atlanta, Georgia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01203618 on ClinicalTrials.govOther trials for Functioning pituitary adenoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07456878Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary AdenomasMayo Clinic
- RECRUITINGNCT07268183How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting TumorsHospices Civils de Lyon
- RECRUITINGPHASE4NCT07045935Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist TreatmentUniversity Hospital, Basel, Switzerland
- RECRUITINGNANCT06584123Molecular Pituitary Imaging Using 18F-FET PETUniversity of Cambridge
- ENROLLING BY INVITATIONNANCT06297473Physical Attendance Versus Telephone or Video Follow-up in Patients With Non-functioning Pituitary Tumors.Zealand University Hospital
- RECRUITINGNANCT06163261Individualized Physical Activity or Patients With Non Functioning Pituitary AdenomaVastra Gotaland Region
- RECRUITINGPHASE4NCT06448195Effects of Growth Hormone Therapy on Metabolic Function in Fatty Liver Post-Pituitary Adenoma SurgeryShanghai Zhongshan Hospital
- RECRUITINGPHASE4NCT04107480PRolaCT - Three Prolactinoma RCTsLeiden University Medical Center